keyword
https://read.qxmd.com/read/38189209/mass-balance-and-metabolite-profile-after-single-and-multiple-oral-doses-of-pritelivir-in-healthy-subjects
#41
JOURNAL ARTICLE
Susanne Bonsmann, David McCormick, Jörg Pausch, Michiel de Vries, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit
Pritelivir is a helicase-primase inhibitor active against HSV. Two human mass balance trials (a multiple-dose trial and a single-dose trial) were performed to characterize the absorption, distribution, metabolism, and excretion of 100 mg oral pritelivir combined with a single microdose of 14 C-pritelivir. Blood, urine, and feces samples were collected up to 26 days postdose. The plasma half-life of pritelivir was 63-67 hours. Overall, 92% and 66% of the administered dose was recovered in the multiple and single dose trials, respectively...
January 8, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38177893/a-comprehensive-review-of-the-clinical-pharmacokinetics-pharmacodynamics-and-drug-interactions-of-nirmatrelvir-ritonavir
#42
REVIEW
Jacqueline Gerhart, Donna S Cox, Ravi Shankar P Singh, Phylinda L S Chan, Rohit Rao, Richard Allen, Haihong Shi, Joanna C Masters, Bharat Damle
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus disease 2019 (COVID-19) treatment. To sustain unbound systemic trough concentrations above the antiviral in vitro 90% effective concentration value (EC90 ), nirmatrelvir is coadministered with 100 mg of ritonavir, a pharmacokinetic enhancer. Ritonavir inhibits nirmatrelvir's cytochrome P450 (CYP) 3A4-mediated metabolism which results in renal elimination becoming the primary route of nirmatrelvir elimination when dosed concomitantly...
January 4, 2024: Clinical Pharmacokinetics
https://read.qxmd.com/read/38176263/rna-four-way-junction-4wj-for-spontaneous-cancer-targeting-effective-tumor-regression-metastasis-suppression-fast-renal-excretion-and-undetectable-toxicity
#43
JOURNAL ARTICLE
Xin Li, Kai Jin, Tzu-Chun Cheng, You-Cheng Liao, Wen-Jui Lee, Abhjeet S Bhullar, Li-Ching Chen, Piotr Rychahou, Mitch A Phelps, Yuan Soon Ho, Peixuan Guo
The field of RNA therapeutics has been emerging as the third milestone in pharmaceutical drug development. RNA nanoparticles have displayed motile and deformable properties to allow for high tumor accumulation with undetectable healthy organ accumulation. Therefore, RNA nanoparticles have the potential to serve as potent drug delivery vehicles with strong anti-cancer responses. Herein, we report the physicochemical basis for the rational design of a branched RNA four-way junction (4WJ) nanoparticle that results in advantageous high-thermostability and -drug payload for cancer therapy, including metastatic tumors in the lung...
December 21, 2023: Biomaterials
https://read.qxmd.com/read/38169355/determination-of-pentoxifylline-efficacy-on-microalbuminuria-in-patients-with-type-2-diabetes
#44
JOURNAL ARTICLE
Shokouh Shayanpour, Aslan Mehri, Fatemeh Hayati, Mehrnoosh Zakerkish, Seyed Seifollah Beladi Mousavi, Khojasteh Hoseinynejad
BACKGROUND: Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria and progressive impairment in renal function. Pentoxifylline is a non-specific inhibitor of phosphodiesterase with anti-inflammatory properties which may have therapeutic potency in patients with diabetic kidney disease. OBJECTIVE: The present study is aimed at evaluating the efficacy of pentoxifylline as a treatment strategy for alleviating the microalbuminuria in type-2 diabetic patients with nephropathy...
January 2024: Recenti Progressi in Medicina
https://read.qxmd.com/read/38164872/phase-i-study-of-the-pharmacokinetics-and-safety-of-single-and-multiple-doses-of-intravenous-n-acetylcysteine-in-healthy-chinese-subjects
#45
JOURNAL ARTICLE
J Sun, X Zhang, L Wang, A F D Di Stefano, V Zanin, P Magrone, Y Yuan
OBJECTIVE: The aim of the study was to determine the pharmacokinetics (PK) and safety of single and repeat doses of intravenous (IV) N-acetylcysteine (NAC) in Chinese subjects. PATIENTS AND METHODS: A total of 24 healthy male and female Chinese subjects aged 19-40 years were enrolled in this open-label phase I study. All subjects received a single dose of NAC 600 mg IV on day 1 and, after a 3-day washout, received repeat doses of NAC 600 mg IV (twice daily on days 4 and 5 and once on day 6)...
December 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38164041/furosemide-attenuates-tubulointerstitial-injury-and-allows-functional-testing-of-porcine-kidneys-during-normothermic-machine-perfusion
#46
JOURNAL ARTICLE
Baran Ogurlu, Tim L Hamelink, Veerle A Lantinga, Henri G D Leuvenink, Merel B F Pool, Cyril Moers
BACKGROUND: Normothermic machine perfusion (NMP) is a promising pretransplant kidney quality assessment platform, but it remains crucial to increase its diagnostic potential while ensuring minimal additional injury to the already damaged kidney. Interventions that alter tubular transport can influence renal function and injury during perfusion. This study aimed to determine whether furosemide and desmopressin affect renal function and injury during NMP. METHODS: Eighteen porcine kidneys (n = 6 per group) were subjected to 30 min of warm ischemia and 4 h of oxygenated hypothermic perfusion before being subjected to 6 h of NMP...
January 1, 2024: Artificial Organs
https://read.qxmd.com/read/38114948/drug-related-problems-and-associated-factors-among-patients-with-kidney-dysfunction-at-a-tertiary-hospital-in-southwestern-uganda-a-prospective-observational-study
#47
JOURNAL ARTICLE
Julius Kyomya, Fredrick Atwiine, Efrata Ashuro Shegena, Rose Muhindo, Tadele Mekuriya Yadesa
BACKGROUND: Kidney dysfunction is a common, progressive condition that is increasingly becoming a global public health issue. Because the kidneys are the major route for drug excretion, impaired renal function can change the pharmacokinetics and pharmacodynamics of drugs that are renally excreted. Additionally, patients with kidney dysfunction often have co-morbidities and the associated use of multiple medications which increases the risk of drug-related problem (DRP) occurrence. This study aimed to determine the prevalence, types, and factors associated with DRPs in patients with kidney dysfunction...
December 19, 2023: BMC Nephrology
https://read.qxmd.com/read/38092719/baclofen-toxicity-in-a-patient-with-end-stage-renal-disease-on-maintenance-dialysis
#48
JOURNAL ARTICLE
Samar Ahmed, Mahmoud Kharrat, Hesham Salah, Fouad Shearyia, Reem Alrimawi, Azizah Makhsoom, Sahal Al Sharif, Rozana Alyami, Faissal Shaheen
Baclofen is a β-(p-chlorophenyl) derivative of the neurotransmitter y-aminobutyrio acid (GABA). This centrally-acting GABA agonist is prescribed as therapy for spasticity in the spinal cord region. The drug is predominantly excreted by the kidney, thus making patients with kidney disease susceptible to side effects. We report on a patient with end-stage renal disease who developed baclofen toxicity, which was successfully treated with intense hemodialysis.
January 1, 2023: Saudi Journal of Kidney Diseases and Transplantation
https://read.qxmd.com/read/38081071/ketoconazole-loading-strategy-to-improve-antifungal-activity-and-overcome-cytotoxicity-on-human-renal-proximal-tubular-epithelial-cells
#49
JOURNAL ARTICLE
Irem Coksu, Yagmur Bozkurt, İlkgul Akmayan, Hasan Demirci, Tulin Ozbek, Serap Acar
Ketoconazole (KTZ), an antifungal agent used to treat localized or systemic fungal infections by inhibiting ergosterol synthesis, exhibits restricted efficacy within eukaryotic cells owing to its elevated toxicity and limited solubility in water. This study aims to improve the biological activity and overcome cytotoxic effects in the renal system of the hydrophobic KTZ by incorporating it into poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) utilizing biomaterial nano-engineering techniques. KTZ-loaded PLGA NPs (KTZ-NPs) were prepared by single emulsion solvent evaporation method and characterized by using dynamic light scattering (DLS), electrophoretic light scattering (ELS), Fourier transform-infrared (FT-IR) spectroscopy and scanning light microscopy (SEM)...
December 11, 2023: Nanotechnology
https://read.qxmd.com/read/38078375/acetazolamide-and-human-carbonic-anhydrases-retrospect-review-and-discussion-of-an-intimate-relationship
#50
REVIEW
Dimitrios Tsikas
Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO2 -NH2 , p K a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II ( K i , 12 nM) and CA IV ( K i , 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO3 - ) and sodium ions (Na+ ) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine...
December 2024: Journal of Enzyme Inhibition and Medicinal Chemistry
https://read.qxmd.com/read/38050337/potassium-homeostasis-and-therapeutic-intervention-with-sodium-zirconium-cyclosilicate-a-model-informed-drug-development-case-study
#51
JOURNAL ARTICLE
Lindsay E Clegg, Lulu Chu, Mats Nagard, David W Boulton, Robert C Penland
Potassium (K+ ) is the main intracellular cation in the body. Elevated K+ levels (hyperkalemia) increase the risk of life-threatening arrhythmias and sudden cardiac death. However, the details of K+ homeostasis and the effects of orally administered K+ binders, such as sodium zirconium cyclosilicate (SZC), on K+ redistribution and excretion in patients remain incompletely understood. We built a fit-for-purpose systems pharmacology model to describe K+ homeostasis in hyperkalemic subjects and capture serum K+ (sK+ ) dynamics in response to acute and chronic administration of SZC...
December 4, 2023: CPT: Pharmacometrics & Systems Pharmacology
https://read.qxmd.com/read/38048851/in-vitro-and-in-vivo-pharmacokinetics-disposition-and-drug-drug-interaction-potential-of-tinengotinib-tt-00420-a-promising-investigational-drug-for-treatment-of-cholangiocarcinoma-and-other-solid-tumors
#52
JOURNAL ARTICLE
Shumao Ni, Lin Li, Xiaofen Sun, Yixiang Wang, Qi Yu, Wuwei Wang, Zheming Gu, Zhenwen Yu, Di Wu, Frank Wu, Shu Jiang, Peng Peng
Early-stage clinical evaluation of tinengotinib (TT-00420) demonstrated encouraging preliminary efficacies in multiple types of refractory cancers, including fibroblast growth factor receptors (FGFR) inhibitors relapsed cholangiocarcinoma (CCA), castrate-resistant prostate cancer (CRPC), and HR+/HER2- breast cancer and triple negative breast cancer (TNBC). To further evaluate drug-like properties of the drug candidate, it is imperative to understand its metabolism and pharmacokinetic properties. This manuscript presented the investigation results of in vitro permeability, plasma protein binding, metabolic stability, metabolite identification, and drug-drug interaction of tinengotinib...
December 2, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38046311/diuretic-potential-of-fenchyl-acetate-with-its-mechanism-of-action-toxicity-study
#53
JOURNAL ARTICLE
Asifa Bashir, Muhammad Naveed Mushtaq, Irfan Anjum, Waqas Younis, Halima Usman, Fareeha Anwar, Musaab Dauelbait, Yousef A Bin Jardan, Mohammed Bourhia
Hypertension has become a global threat and is one of the greatest risk factors for chronic kidney disease. Fenchyl acetate is a monoterpene that has been assessed for its various pharmacological activities in the past, but no study has evaluated its diuretic potential and the mechanism involved in the diuretic activity after prolonged administration in rats. Therefore, this study aimed to measure the safety and diuretic profile of fenchyl acetate in rats. For evaluating the acute toxicity, a single dose of 2000 mg/kg was administered as per the OECD guideline no...
November 28, 2023: ACS Omega
https://read.qxmd.com/read/38045996/drugs-with-a-negative-impact-on-cognitive-function-part-1-chronic-kidney-disease-as-a-risk-factor
#54
REVIEW
Sophie Liabeuf, Vesna Pešić, Goce Spasovski, Romaldas Maciulaitis, Mickaël Bobot, Ana Farinha, Carsten A Wagner, Robert J Unwin, Giovambattista Capasso, Inga Arune Bumblyte, Gaye Hafez
People living with chronic kidney disease (CKD) frequently suffer from mild cognitive impairment and/or other neurocognitive disorders. This review in two parts will focus on adverse drug reactions resulting in cognitive impairment as a potentially modifiable risk factor in CKD patients. Many patients with CKD have a substantial burden of comorbidities leading to polypharmacy. A recent study found that patients seen by nephrologists were the most complex to treat because of their high number of comorbidities and medications...
December 2023: Clinical Kidney Journal
https://read.qxmd.com/read/38037664/pharmacokinetics-and-tumor-delivery-of-nanoparticles
#55
JOURNAL ARTICLE
Long Yuan, Qiran Chen, Jim E Riviere, Zhoumeng Lin
Nanoparticles (NPs) have been widely used in different areas, including consumer products and medicine. In terms of biomedical applications, NPs or NP-based drug formulations have been extensively investigated for cancer diagnostics and therapy in preclinical studies, but the clinical translation rate is low. Therefore, a thorough and comprehensive understanding of the pharmacokinetics of NPs, especially in drug delivery efficiency to the target therapeutic tissue tumor, is important to design more effective nanomedicines and for proper assessment of the safety and risk of NPs...
May 2023: Journal of Drug Delivery Science and Technology
https://read.qxmd.com/read/38034420/clinical-remission-of-severe-crohn-s-disease-with-empagliflozin-monotherapy-in-a-pediatric-patient-with-glycogen-storage-disease-type-1b
#56
Lauren V Collen, Peter E Newburger, Scott B Snapper
Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy.
November 2023: JPGN reports
https://read.qxmd.com/read/38031322/a-physiological-approach-to-renal-clearance-from-premature-neonates-to-adults
#57
JOURNAL ARTICLE
Nick Holford, Conor J O'Hanlon, Karel Allegaert, Brian Anderson, Amilcar Falcão, Nicolas Simon, Yoke-Lin Lo, Alison H Thomson, Catherine M Sherwin, Evelyne Jacqz-Aigrain, Carolina Llanos-Paez, Stefanie Hennig, Linas Mockus, Carl Kirkpatrick
AIMS: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance. METHODS: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age, and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients...
November 29, 2023: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38027649/the-nephrotoxicity-of-aristolochia-rotunda-l-in-rats-mitochondrion-as-a-target-for-renal-toxicity-of-aristolochic-acids-containing-plants
#58
JOURNAL ARTICLE
Zohreh Abolhassanzadeh, Simin Ansari, Zahra Lorigooini, Maryam Anjomshoa, Elham Bijad, Pantea Ramezannezhad, Mohammad Hadi Zarei
In recent years, there has been a growing trend in the usage of traditional medicine and herbal treatments. However, the misconception that they are completely safe resulted in irreversible complications and damages. The present study was conducted to investigate the potential renal toxicity of a commonly used drug in Iran's traditional medicine and pharmacy, known as Zaravand Gerd or Nokhod Alvand ( Aristolochia rotunda L.). In Iranian traditional medicine, Zaravand Gerd is used as a remedy for respiratory system ailments, back pain, anxiety, headache and septic wounds...
November 2023: Heliyon
https://read.qxmd.com/read/38025218/randomized-trial-comparing-sglt2-inhibition-and-hydrochlorothiazide-on-sympathetic-traffic-in-type-2-diabetes
#59
JOURNAL ARTICLE
Karsten Heusser, Jens Tank, André Diedrich, Annelie Fischer, Tim Heise, Jens Jordan
INTRODUCTION: Reductions in sympathetic nervous system activity may contribute to beneficial effects of sodium glucose cotransporter 2 (SGLT2) inhibition on cardiovascular outcomes. Therefore, we tested the hypothesis that SGLT2 inhibition with empagliflozin (Empa) lowers muscle sympathetic nerve activity (MSNA) in patients with type 2 diabetes mellitus (T2DM) compared with hydrochlorothiazide (HCT) to discern SGLT2-specific actions from responses to increased natriuresis. METHODS: We randomized patients with T2DM on metformin monotherapy to either 25 mg/d Empa ( n  = 20) or 25 mg/d HCT ( n  = 21) for 6 weeks in a parallel, double-blind fashion...
November 2023: KI Reports
https://read.qxmd.com/read/38024860/albumin-bound-kynurenic-acid-is-an-appropriate-endogenous-biomarker-for-assessment-of-the-renal-tubular-oats-mrp4-channel
#60
JOURNAL ARTICLE
Yanrong Ma, Fenglin Ran, Mingyan Xin, Xueyan Gou, Xinyi Wang, Xinan Wu
Renal tubular secretion mediated by organic anion transporters (OATs) and the multidrug resistance-associated protein 4 (MRP4) is an important means of drug and toxin excretion. Unfortunately, there are no biomarkers to evaluate their function. The aim of this study was to identify and characterize an endogenous biomarker of the renal tubular OATs-MRP4 channel. Twenty-six uremic toxins were selected as candidate compounds, of which kynurenic acid was identified as a potential biomarker by assessing the protein-binding ratio and the uptake in OAT1-, OAT3-, and MRP4-overexpressing cell lines...
October 2023: Journal of Pharmaceutical Analysis
keyword
keyword
106291
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.